Drug Targeting Organ-Specific Strategies

20 1 Drug Targeting: Basic Concepts and Novel Advances
References
[1] Breimer DD, Adv. Drug Deliv. Rev. 1998, 33, 265–268.
[2] Mastrobattista E, Koning GA, Storm G, Adv. Drug Deliv. Rev. 1999, 40, 103–127.
[3] Duzgunes N, Nir S, Adv. Drug Deliv. Rev. 1999, 40, 3–18.
[4] Storm G, Crommelin DJA, PSTT 1998, 1, 19–31.
[5] Köhler G, Milstein C, Nature 1975, 256, 495–497.
[6] Farah RA, Clinchy B, Herrera L, Vitetta ES, Crit. Rev. Eukaryot. Gene Expr. 1998, 8, 321–356.
[7] Willuda J, Honegger A, Waibel R, Schubiger PA, Stahel R, Zangemeister-Wittke U, Pluckthun
A, Cancer Res. 1999, 59, 5758–5767.
[8] Worn A, Pluckthun A, Biochemistry 1999, 38, 8739–8750.
[9] Charles P, Elliott MJ, Davis D, Potter A, Kalden JR, Antoni C, Breedveld FC, Smolen JS, Eberl
G, deWoody K, Feldmann M, Maini RN, J. Immunol. 1999, 163, 1521–1528.
[10] Beljaars L, Molema G, Schuppan D, Geerts A, de Bleser PJ, Weert B, Meijer DKF, Poelstra K, J.
Biol. Chem. 2000, 275, 12743–12751.
[11] Molema G, Meijer DKF, Adv. Drug Deliv. Rev. 1994, 14, 25–50.
[12] Ogawara K, Hasegawa S, Nishikawa M, Takakura Y, Hashida M, J. Drug Target. 1999, 6, 349–360.
[13] Stehle G, Sinn H, Wunder A, Schrenk HH, Schutt S, Maier Borst W, Heene DL, Anticancer Drugs
1997, 8, 677–685.
[14] Maeda H, Wu J, Sawa T, Matsumura Y, Hori K, J. Control. Rel. 2000, 65, 271–284.
[15] Vasey PA, Kaye SB, Morrison R, Twelves C, Wilson P, Duncan R, Thomson AH, Murray
LS, Hilditch TE, Murray T, Burtles S, Fraier D, Frigerio E, Cassidy J, Clin. Cancer Res. 1999, 5,
83–94.
[16] Gianasi E, Wasil M, Evagorou EG, Keddle A, Wilson G, Duncan R, Eur. J. Cancer 1999, 35,
994–1002.
[17] Sawa T, Wu J, Akaike T, Maeda H, Cancer Res. 2000, 60, 666–671.
[18] Richardson SC, Kolbe HV, Duncan R, Int. J. Pharm. 1999, 178, 231–243.
[19] Malik N, Wiwattanapatapee R, Klopsch R, Lorenz K, Frey H, Weener JW, Meijer EW, Paulus W,
Duncan R, J. Control. Rel. 2000, 65, 133–148.
[20] Lu ZR, Kopeckova P, Kopeček J, Nature Biotechnol. 1999, 1, 1101–1104.
[21] Kader A, Davis PJ, Kara M, Liu H, J. Control. Rel. 1998, 55, 231–243.
[22] Meijer DKF, Molema G, Sem. Liver Dis. 1995, 15, 202–256.
[23] de Vrueh RL, Rump ET, van De BE, van Veghel R, Balzarini J, Biessen EA, van Berkel TJ,
Bijsterbosch MK, Antimicrob. Agents Chemother. 2000, 44, 477–483.
[24] Van Velzen AG, Da Silva RP, Gordon S, van Berkel TJ, Biochem. J. 1997, 322 (Pt 2), 411–415.
[25] Ling W, Lougheed M, Suzuki H, Buchan A, Kodama T, Steinbrecher UP, J. Clin. Invest. 1997, 100,
244–252.
[26] Utreja S, Khopade AJ, Jain NK, Pharm. Acta Helv. 1999, 73, 275–279.
[27] Muller RH, Mader K, Gohla S, Eur. J. Pharm. Biopharm. 2000, 50, 161–177.
[28] Aynie I, Vauthier C, Chacun H, Fattal E, Couvreur P, Antisense Nucl. Acid Drug Dev. 1999, 9,
301–312.
[29] Soma CE, Dubernet C, Bentolila D, Benita S, Couvreur P, Biomaterials 2000, 21, 1–7.
[30] Allemann E, Leroux J, Gurny R, Adv. Drug Deliv. Rev. 1998, 34, 171–189.
[31] Pecquet S, Leo E, Fritsche R, Pfeifer A, Couvreur P, Fattal E, Vaccine 2000, 18, 1196–1202.
[32] Jones M, Leroux J, Eur. J. Pharm. Biopharm. 1999, 48, 101–111.
[33] Yokoyama M, Okano T, Sakurai Y, Fukushima S, Okamoto K, Kataoka K, J. Drug Target. 1999,
7, 171–186.
[34] Vallera DA, Jin N, Baldrica JM, Panoskaltsis-Mortari A, Chen SY, Blazar BR, Cancer Res. 2000,
60, 976–984.
[35] Wiedle G, Johnson-Leger C, Imhof BA, Cancer Res. 1999, 59, 5255–5263.
[36] Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman
G, Isner JM, Science 1997, 275, 964–967.
[37] Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H, Inai Y, Silver M, Isner JM,
EMBO J. 1999, 18, 3964–3972.
[38] Isner JM, Asahara T, J. Clin. Invest 1999, 103, 1231–1236.
[39] Moghimi SM, Rajabi-Siahboomi AR, Adv. Drug Deliv. Rev. 2000, 41, 129–133.
[40] Stayton PS, Hoffman AS, Murthy N, Lackey C, Cheung C, Tan P, Klumb LA, Chilkoti A, Wilbur
FS, Press OW, J. Control. Rel. 2000, 65, 203–220.
[41] Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF, Science 1999, 285, 1569–1572.